A retrospective study analyzed the intrapatient heterogeneity of 18 F-FES PET as a prognostic factor in 102 patients with mBC and demonstrated that patients with ER-positive homogenous expression showed a trend toward longer outcomes as compared with those with heterogenous expression [ 10 , 11 ].
← all excerpts
Could <sup>18</sup>F-FES PET Be a New Driver in Therapeutic Choice for Metastatic HR+/HER2- Patients?
1
—
—